1
|
Shayo E, Van Hout MC, Birungi J, Garrib A, Kivuyo S, Mfinanga S, Nyrienda MJ, Namakoola I, Okebe J, Ramaiya K, Bachmann MO, Cullen W, Lazarus JV, Gill G, Shiri T, Bukenya D, Snell H, Nanfuka M, Cuevas LE, Shimwela M, Mutungi G, Musinguzi J, Mghamba J, Mugisha K, Jaffar S, Smith PG, Sewankambo NK. Ethical issues in intervention studies on the prevention and management of diabetes and hypertension in sub-Saharan Africa. BMJ Glob Health 2020; 5:bmjgh-2019-002193. [PMID: 32636311 PMCID: PMC7342469 DOI: 10.1136/bmjgh-2019-002193] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2019] [Revised: 06/02/2020] [Accepted: 06/05/2020] [Indexed: 11/30/2022] Open
Affiliation(s)
- Elizabeth Shayo
- National Institutes for Medical Research, Dar es Salaam, United Republic of Tanzania
| | - Marie Claire Van Hout
- Faculty of Education, Health & Community, Liverpool John Moores University, Liverpool, Merseyside, UK
| | | | - Anupam Garrib
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Sokoine Kivuyo
- National Institutes for Medical Research, Dar es Salaam, United Republic of Tanzania
| | - Sayoki Mfinanga
- National Institutes for Medical Research, Dar es Salaam, United Republic of Tanzania
| | - Moffat J Nyrienda
- MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda.,Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine, London, UK
| | | | - Joseph Okebe
- Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK
| | | | - Max Oscar Bachmann
- Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK
| | - Walter Cullen
- School of Medicine, University College Dublin, Dublin, Ireland
| | - Jeffrey V Lazarus
- Hospital Clinic, University of Barcelona, Instituto de Salud Global de Barcelona, Barcelona, Spain.,CHIP, Rigshospitalet, Kobenhavn, Denmark
| | - Geoff Gill
- Emeritus Professor of International Medicine, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Tinevimbo Shiri
- Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK
| | | | - Hazel Snell
- Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK
| | | | - Luis E Cuevas
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | | | - Gerald Mutungi
- Non-communicable Disease Control Programme, Ministry of Health, Kampala, Uganda
| | | | - Janneth Mghamba
- Department of Preventive Services, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania
| | | | - Shabbar Jaffar
- Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK
| | - Peter G Smith
- MRC Tropical Epidemiology Group, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
| | | |
Collapse
|
3
|
Loubiere S, el Filal KM, Sodqi M, Loundou A, Luchini S, Cleary S, Moatti JP, Himmich H. When to Initiate Highly Active Antiretroviral Therapy in Low-Resource Settings: The Moroccan Experience. Antivir Ther 2008. [DOI: 10.1177/135965350801300209] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background The aim of this study was to assess the cost-effectiveness of HIV treatment alternatives – with and without highly active antiretroviral therapy (HAART) – within alternative strata based on the CD4+ T-cell count at the initiation of treatment in a low-resource setting. Methods A retrospective observational study was conducted following 286 HIV-positive individuals admitted to the principal teaching hospital in Casablanca, Morocco, between 1995 and 2002. Patients were stratified by CD4+ T-cell count and regression models were fitted to determine risk of opportunistic infection. Data on healthcare resource use were derived from patient records and were evaluated from the hospital perspective. Results HAART led to a significant reduction in the number of HIV-related opportunistic infections ( P<0.0001), extended survival (61.3 versus 55.2 months; P<0.0001) and reduced hospital stays ( P<0.0001) in comparison with care in the absence of HAART. When medical care and drug costs were considered together, HAART was more costly than providing treatment for opportunistic infections. The incremental cost-effectiveness ratio was lower than gross domestic product (GDP) per capita for patients starting HAART with a CD4+ T-cell count <200 cells/mm3, but this increased to nearly three times GDP per capita when HAART was initiated at CD4+ T-cell counts above this threshold. Conclusions HAART is more cost-effective than treating HIV-related opportunistic infections and, contrary to conclusions drawn in developed countries, HAART is more cost-effective when the CD4+ T-cell count drops to <200 cells/mm3.
Collapse
Affiliation(s)
- Sandrine Loubiere
- Health and Medical Research National Institute (INSERM), Research Unit UMR 912, Marseilles, France
- Southeastern Health Regional Observatory (ORS PACA), Marseilles, France
| | | | - Mustapha Sodqi
- Infectious Disease Unit, Hospital Ibn Rochd, 20100 Casablanca, Morocco
| | - Anderson Loundou
- Department of Public Health, Timone University Hospital, Marseilles, France
| | - Stéphane Luchini
- Health and Medical Research National Institute (INSERM), Research Unit UMR 912, Marseilles, France
- GREQAM-CNRS, Marseilles, France
| | - Susan Cleary
- Health Economics Unit, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa
| | - Jean-Paul Moatti
- Health and Medical Research National Institute (INSERM), Research Unit UMR 912, Marseilles, France
- Southeastern Health Regional Observatory (ORS PACA), Marseilles, France
| | - Hakima Himmich
- Infectious Disease Unit, Hospital Ibn Rochd, 20100 Casablanca, Morocco
| |
Collapse
|